Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya (doi:10.7910/DVN/FPUH4R)

View:

Part 1: Document Description
Part 2: Study Description
Part 3: Data Files Description
Part 5: Other Study-Related Materials
Entire Codebook

Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya

doi:10.7910/DVN/FPUH4R

Harvard Dataverse

2023-12-14

2

Downs, Louise O.; Campbell, Cori; Abouyannis, Michael; Otiende, Mark.; Kapulu, Melissa; Obiero, Christine W.; Hamaluba, Mainga; Ngetsa, Caroline; Andersson, Monique; Githinji, George; Warimwe, George; Baisley,Kathy; Scott, J. Anthony G.; Matthews, Philippa C.; Etyang, Anthony, 2023, "Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya", https://doi.org/10.7910/DVN/FPUH4R, Harvard Dataverse, V2, UNF:6:j45hG2yDzzDcraiGWjiNSA== [fileUNF]

Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya

doi:10.7910/DVN/FPUH4R

Downs, Louise O. (University of Oxford, KEMRI-Wellcome Trust Research Programme)

Campbell, Cori (University of Oxford)

Abouyannis, Michael (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Otiende, Mark. (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Kapulu, Melissa (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Obiero, Christine W. (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Hamaluba, Mainga (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Ngetsa, Caroline (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

Andersson, Monique (University of Oxford)

Githinji, George (KEMRI-Wellcome Trust Programme, Kilifi, Kenya)

Warimwe, George (KEMRI-Wellcome Trust Programme, Kilifi, Kenya)

Baisley,Kathy (London School of Hygiene and Tropical Medicine)

Scott, J. Anthony G. (KEMRI-Wellcome Trust Programme, Kilifi, Kenya)

Matthews, Philippa C. (Francis Crick Institute, University College London, University College London Hospitals)

Etyang, Anthony (KEMRI-Wellcome Trust Programme, Kilifi, Kenya)

Harvard Dataverse

Downs, Louise O.

The Data Governance Committee

Downs, Louise O.

2023-12-14

https://doi.org/10.7910/DVN/FPUH4R

Medicine, Health and Life Sciences, Chronic hepatitis B, Clinical trials, Seroprevalence, Elimination Goals, Clinical care

<p>This is a replication dataset for the manuscript titled: "<a href="">Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya</a>."</p>. <p>This is a dataset summarising demographic, hepatitis B test results and alanine aminotransferase data from 6 completed different clinical trials conducted at KEMRI-Wellcome Trust Research Programme since 2016. The aim of this work was to give a seroprevalence estimate for HBV in Kilifi and also illustrate the amount of data that is likely available in this space that is currently underutilised. Data were accessed with permission from study PIs and from sponsors where necessary. These data were standardised for age and sex using the Kilifi health and demographic surveillance system (KHDSS) data as the standard population structure.</p> <p>This data showed a crude HBsAg seroprevalence rate of 3.5%, which rose to 5% when standardised. There was considerable underrepresentation of women in these trials with 77% of participants being male. ALT was significantly higher in those who were HBsAg positive compared to negative, although was not outside the upper limit of normal for this population. </p> <p>We argue from these results that routine collection and collation of both blood borne virus prevalence and liver function test information will enable better modelling of not only blood borne viruses, but also for estimating the burden from liver disease across the African region. This would be a low cost, efficient method that negates the need for the organisation of large sero-epidemiological surveys</p>

<strong>Data Availability</strong> <p>Access to these data requires submission of a formal request for consideration by our Data Governance Committee. </p> <strong>How to request</strong> <ol> <li>Download and complete the <a href="https://kemri-wellcome.org/zp-content/uploads/2021/02/KWTRP_Dataverse_Data_Request_Form_2019.docx"><strong>data request form</strong></a></li> <li> Email completed data request form to the Data Governance Committee at <a href="mailto:dgc@kemri-wellcome.org?cc=lmwango@kemri-wellcome.org?Subject=Data%20Access%20Request"><strong>dgc@kemri-wellcome.org</strong></a> </li> </ol>

For access to data and more detailed information beyond the metadata and documentation provided, please send a signed data request form to [<a href="mailto:dgc@kemri-wellcome.org">dgc@kemri-wellcome.org</a> ]. <strong> <a href="https://kemri-wellcome.org/zp-content/uploads/2021/02/KWTRP_Dataverse_Data_Request_Form_2019.docx">Click to download Data Request Form</a></strong>

• Number of cases: 49

• No. of variables per record: 7

• Type of File: text/tab-separated-values

UNF:6:F28euGp1G0gVaJ03whaiTw==

• Number of cases: 1731

• No. of variables per record: 5

• Type of File: text/tab-separated-values

UNF:6:vC7OrJDKfaxmpFCU35L6nw==

Label:

20230712_age_stanrardized_prevalence.do

application/x-stata-syntax

Label:

HBV seroprevalence data_variable codebook.pdf

application/pdf

Label:

Seroprevalence code for curation.R

type/x-r-syntax

Label:

Seroprevalence data info for curation.txt

text/plain